Effect of an Exercise on Serum Uncoupling Protein-1 Level and the Role of Uncoupling Protein-1-3826 A/G Polymorphism
The Effect of an Acute Maximal Exercise on Serum Uncoupling Protein-1 Level and the Role of Uncoupling Protein-1-3826 A/G Polymorphism
1 other identifier
interventional
86
1 country
1
Brief Summary
This study aims to determine the effect of an acute maximal exercise on serum uncoupling protein-1, irisin, interleukin 6 levels, and on blood lipid and lipoprotein concentrations. This study also evaluates the role of uncoupling protein-1-3826 A/G polymorphism on this eventual effect. Therefore, this study hypothesizes that: H01: Sedentary people and athletes' serum uncoupling protein 1, irisin, and interleukine 6 levels are different before and after an acute maximal exercise. H02: Sedentary people and athletes' basal serum uncoupling protein 1 levels are associated with uncoupling protein 1-3826 A/G polymorphism. H03: Uncoupling protein 1-3826 A/G polymorphism has a modifying role in the effect of maximal exercise on serum uncoupling protein 1 levels. H04: Sedentary people and athletes' basal serum lipid and lipoprotein levels are associated with uncoupling protein 1-3826 A/G polymorphism. H05: Uncoupling protein 1-3826 A / G polymorphism has a modifying role in the effect of maximal exercise on serum lipid and lipoprotein levels.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Nov 2019
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 4, 2019
CompletedFirst Posted
Study publicly available on registry
November 7, 2019
CompletedStudy Start
First participant enrolled
November 11, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 2, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
September 7, 2020
CompletedSeptember 9, 2020
September 1, 2020
10 months
November 4, 2019
September 7, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Change from the baseline serum uncoupling protein 1 level at 3 minutes post Yo-Yo intermittent recovery test (level 1)
Volunteers' postprandial venous blood samples were taken 15 minutes before the Yo-Yo intermittent recovery test (level 1) and 3 minutes post test. Uncoupling protein 1 analyzes were performed in the laboratory.
15 minutes before and 3 minutes after the Yo-Yo intermittent recovery test (level 1)
Change from the baseline serum irisin level at 3 minutes post Yo-Yo intermittent recovery test (level 1)
Volunteers' postprandial venous blood samples was taken 15 minutes before the Yo-Yo intermittent recovery test (level 1) and 3 minutes post test. Irisin analyzes were performed in the laboratory.
15 minutes before and 3 minutes after the Yo-Yo intermittent recovery test (level 1)
Uncoupling protein-1-3826 A/G polymorphism determination
Volunteers' postprandial venous blood samples were taken 15 minutes before the Yo-Yo intermittent recovery test (level 1). Polymorphism was determined in the laboratory.
15 minutes before the Yo-Yo intermittent recovery test (level 1)
Secondary Outcomes (2)
Change from the baseline serum interleukin-6 level at 3 minutes post Yo-Yo intermittent recovery test (level 1)
15 minutes before and 3 minutes after the Yo-Yo intermittent recovery test (level 1)
Change from the baseline serum nitric oxide level at 3 minutes post Yo-Yo intermittent recovery test (level 1)
15 minutes before and 3 minutes after the Yo-Yo intermittent recovery test (level 1)
Other Outcomes (15)
Change from the baseline serum C reactive protein level at 3 minutes post Yo-Yo intermittent recovery test (level 1)
15 minutes before and 3 minutes after the Yo-Yo intermittent recovery test (level 1)
Change from the baseline serum creatine kinase level at 3 minutes post Yo-Yo intermittent recovery test (level 1)
15 minutes before and 3 minutes after the Yo-Yo intermittent recovery test (level 1)
Change from the baseline serum alanine aminotransferase level at 3 minutes post Yo-Yo intermittent recovery test (level 1)
15 minutes before and 3 minutes after the Yo-Yo intermittent recovery test (level 1)
- +12 more other outcomes
Study Arms (2)
Athletes Group
EXPERIMENTALThe athletes group will be composed of healthy, non obese (body mass index \< 30), male basketball, volleyball and handball players aged between 18 and 35 years who have been training regularly for at least 3 months. Participants must not be regular consumer of cigarettes, alcohol, drugs and antioxidant substances. Intervention: Yo-Yo intermittent recovery test (level 1) is administered.
Sedentary Group
EXPERIMENTALThe sedentary group will be composed of healthy, non obese (body mass index \< 30), male aged between 18 and 35 years who have not been training regularly for at least 3 months. Participants must not be regular consumer of cigarettes, alcohol, drugs and antioxidant substances. Intervention: Yo-Yo intermittent recovery test (level 1) is administered.
Interventions
The Yo-Yo intermittent recovery test (level 1) will be administered once.
Eligibility Criteria
You may qualify if:
- Athletes group:
- Must be basketball, or volleyball, or handball players.
- Must be subjects who have been training regularly for at least 3 months.
- Sedentary group:
- \* Must be subjects who have not been training regularly for at least 3 months.
- For both groups:
- Healthy.
- Non obese (body mass index \< 30).
- Aged between 18 and 35 years.
You may not qualify if:
- For both groups:
- Being regular consumer of cigarettes, alcohol, drugs and antioxidant substances.
- Being obese (body mass index \> 30).
- Having an acute or chronic injury which is limiting physical performance.
- Having a disease (anemia, infection...) detected from the biochemical analysis of the blood samples.
- Being injured or sick during the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Eastern Mediterranean Universitylead
- Ege Universitycollaborator
Study Sites (1)
Ege University Faculty of Sport Sciences
Izmir, Turkey (Türkiye)
Study Officials
- STUDY CHAIR
Faruk Turgay, Assoc. Prof
Ege University, Faculty of Sports Science
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Senior instructor
Study Record Dates
First Submitted
November 4, 2019
First Posted
November 7, 2019
Study Start
November 11, 2019
Primary Completion
September 2, 2020
Study Completion
September 7, 2020
Last Updated
September 9, 2020
Record last verified: 2020-09